CoChat

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Open access

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-017-0524-2

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 124

Metadata

Authors
Colen, R. R., Fujii, T., Bilen, M. A., Kotrotsou, A., Abrol, S., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Giniebra-Camejo, D., Stephen, B., Subbiah, V., Sheshadri, A., Mendoza, T., Fu, S., Sharma, P., Meric-Bernstam, F., & Naing, A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Baylor College of Medicine (US)
Corresponding author
  • Colen, Rivka R.
  • Naing, Aung
Venue
Investigational New Drugs
Published
2017-10-27
Volume
36
Issue
4
Pages
601-607
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2766233251
Cited by
120
References
34
Citations by year
2026: 7 · 2025: 12 · 2024: 9 · 2023: 16 · 2022: 15 · 2021: 22 · 2020: 22 · 2019: 8 · 2018: 8 · 2017: 1
FWCI
8.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Cancer Prevention and Research Institute of Texas (RP160150)
  • John S. Dunn Sr. Distinguished Chair in Diagnostic Imaging Fund
  • The University of Texas MD Anderson Cancer Center startup funding
  • The University of Texas MD Anderson Cancer Center support grant (P30 CA016672)
  • K23 Career Development Award, National Institutes of Health (K23AI117024)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Physical Sciences › Computer Science › Computer Vision and Pattern Recognition › Image Retrieval and Classification Techniques
Keywords
radiomics, immune-related adverse events, risk prediction, chest CT, radiomic feature selection, risk stratification, early detection
MeSH terms
Adult, Aged, Female, Humans, Immunologic Factors, Immunotherapy, Male, Middle Aged, Pilot Projects, Pneumonia, Risk, Biomarkers, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.